Diseases, Conditions, Syndromes

Adalimumab reduces inflammation in refractory pediatric uveitis

A new study published in the current issue of the Journal of the American Association for Pediatric Ophthalmology and Strabismus (AAPOS) suggests that the biologic agent adalimumab may be a viable treatment option for patients ...

Diseases, Conditions, Syndromes

ABP 501, adalimumab biosimilar, safe and effective, for psoriasis

(HealthDay)—The biosimilar ABP 501 has similar clinical efficacy and safety to adalimumab for the treatment of moderate-to-severe plaque psoriasis, according to a study published online July 28 in the British Journal of ...

Medications

Upadacitinib beats placebo for psoriatic arthritis

For patients with psoriatic arthritis, upadacitinib at a dose of 15 mg or 30 mg once daily is more effective than placebo, according to a study published in the April 1 issue of the New England Journal of Medicine.

Arthritis & Rheumatism

Abatacept as effective as adalimumab in rheumatoid arthritis

Data from AMPLE presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, demonstrate comparable efficacy and similar safety profiles between subcutaneous abatacept (ABA) and adalimumab (ADA).

Medications

Patient expresses concern about lack of data on biological drugs

(HealthDay)—A patient with Crohn's disease is concerned about the attempt by the makers of adalimumab to prevent disclosure of trial data submitted during the drug's approval process, according to a personal view piece ...

Diseases, Conditions, Syndromes

Frequently used biologic agents might cause acute liver injury

A commonly used class of biologic response modifying drugs can cause acute liver injury with elevated liver enzymes, according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal ...

Medications

No need for discontinuation of Adalimumab before surgery

Hidradenitis suppurativa (Syn. Acneinversa) is one of the most troublesome and complicated skin diseases. The anti-inflammatory drug adalimumab can improve symptoms; however, patients also often have to undergo surgery. Until ...

Arthritis & Rheumatism

Using antibodies against immune deficiency

Early, intensive therapy with a biotechnologically produced medication can provide significantly faster pain relief for patients with rheumatic joint inflammation. Damage to joints can also be reduced when the medication ...

page 4 from 5